HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) All Versions of this Article: db07-1775v1 57/7/1926    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Picha, K. M. Articles by O'Neil, K. T. PubMed PubMed Citation Articles by Picha, K. M. Articles by O'Neil, K. T. Social Bookmarking                What's this?

Protein Engineering Strategies for Sustained GLP-1R-Dependent Control of Glucose Homeostasis

Discovery Research, Centocor R&D Inc. 145 King of Prussia Road, Radnor, PA 19087 USA
^#Samuel Lunenfeld Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, Ontario, Canada

Objective: We have developed a novel platform for display and delivery of bioactive peptides that links the biological properties of the peptide to the pharmacokinetic properties of an antibody. Peptides engineered in the MIMETIBODY^TM platform have improved biochemical and biophysical properties quite distinct from those of Fc-fusion proteins. CNTO736 is a GLP-1 receptor agonist engineered in our MIMETIBODY^TM platform. It retains many activities of native GLP-1 yet has a significantly enhanced pharmacokinetic profile. Our goal was to develop a long acting GLP-1 receptor agonist with sustained efficacy.

Research Design and Methods: In vitro and in vivo activity of CNTO736 was evaluated using a variety of rodent cell lines and diabetic animal models.

Results: Acute pharmacodynamic studies in diabetic rodents demonstrate that CNTO736 reduces fasting and postprandial glucose, decreases gastric emptying, and inhibits food intake in a GLP-1R-specific manner. Reduction of food intake following CNTO736 dosing is coincident with detection of the molecule in the circumventricular organs of the brain and activation of c-fos in regions protected by the blood brain barrier. Diabetic rodents dosed chronically with CNTO736 have lower fasting and postprandial glucose and reduced body weight.

Conclusions: Taken together, our data demonstrate that CNTO736 produces a spectrum of GLP-1R-dependent actions while exhibiting significantly improved pharmacokinetics relative to the native GLP-1 peptide.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?